TJ
Stock/Options Trader, Volume at Support/Resistance, Publisher of Volume Stocks Newsletter
Hims & Hers faces mounting headwinds from an FTC lawsuit and a setback to its peptide expansion. The FTC alleges deceptive subscription practices and improper sharing of sensitive health data with ad platforms. An FDA advisory panel also voted against adding emideltide to the 503A Bulks List, a blow to Hims' peptide and compounding plans. x.comÂ
Hims & Hers faces a bigger question over its peptide business after an FDA panel rejected its Emideltide peptide, and the chart leans bearish. Concerns about access for uninsured patients added pressure, and the stock gave back a chunk of its 2026 gains in days. A rounding top has been confirmed on massive volume. Staying below the 31.62 neckline confirms the breakdown toward 25.80 and 21.53, while reclaiming it would stall the pattern. x.com x.comÂ
Hims & Hers looks good on paper, but past revenue growth does not guarantee future growth and margins are falling, which is very bad. Its peptides story could rerate the stock if executed, but it brings another regulatory overhang: peptides will be in regulation headlines every day and the stock will trade on them. x.comÂ
Hims & Hers looks bearish on news that Chinese producers are moving into bootleg peptides sold in the US. Per a WSJ report shared by @tradfi, Chinese fentanyl precursor producers are pivoting to selling bootleg peptides in the US, and several Chinese peptide vendors were previously indicted in the US over the fentanyl trade. x.comÂ
RFK Jr.'s health department's notice that the FDA will not take action against pharmacies compounding six unapproved peptides brings Hims & Hers' peptide opportunity forward. Pharmacies can offer BPC-157, TB-500, epitalon, KPV, MOTS-c and semax now while a formal rule change is worked on. This is the most bullish news for Hims & Hers. x.comÂ
Hims & Hers suffers from bad management, and government pressure is squeezing its pharma margins. x.comÂ
Hims & Hers' latest earnings show a deteriorating business, and hype is not worth much when that happens. x.com x.comÂ
Hims & Hers' peptide capabilities may be underappreciated, setting up a strong bounce after peptide news. Per @riyadosofian, it is the only telehealth company with a peptide facility and global distribution system. A strong bounce is expected now as the stock holds outside its wedge. x.com x.comÂ
Hims & Hers' peptide business looks undifferentiated with relatively low barriers to entry, since nothing about providing peptides appears proprietary. Its edge would have to be scale and distribution, and it is not clear it is far ahead of other telehealth companies there. @JonahLupton notes Barron's said Hims could own 20% of the peptide market. x.comÂ
Hims & Hers is getting hit by Amazon, a competitor using its own generic product to undercut the Hims generic offering. x.comÂ
Hims & Hers' newly previewed Peptides+ offering could add a growth vertical to its healthcare platform. Management plans access to sermorelin, glutathione and NAD+; recent regulatory developments may also open a path for BPC-157 and TB-500, subject to further conditions. Rollout and commercial opportunity remain unproven, and margins and execution are still risks. x.comÂ
Hims & Hers is one to avoid because it has been forced out of higher-margin compounded GLP-1s into lower-margin business. x.comÂ
